<Case Reports> Recognition of complete response by long-term observation after treatment with ^<90>Y-Ibritumomab tiuxetan for relapsed follicular lymphoma

[Abstract] Monoclonal antibodies have markedly changed the treatment possibilities for patients with indolent B-cell lymphoma. ^Y-Ibritumomab tiuxetan (Zevalin) is the first radioimmunotherapy (RIT) agent approved for the treatment of relapsed and refractory indolent lymphoma patients. In most cases, the maximum clinical response were observed two to three months after RIT. Treatment with ^Y-ibritumomab tiuxetan may have potential late effects in some cases of relapsed follicular lymphomas, and we must be careful to start the next treatment after RIT.